Journal article

Koyuncu et al 2020 – Evaluation of the performance of the Turkish regulatory agency: recommendations for improved patients’ access to medicines

Background: This study was to evaluate the Turkish regulatory review process and timelines between 2016 and 2018 with a view to assess the changes that had taken place since [...]

2026-02-05T16:35:16+00:00February 3rd, 2020|Tags: , |

Keyter et al 2019 – Evaluation of the performance of the South African regulatory agency

Background: Timely access to new medicines may be addressed through strengthening of registration efciencies and timelines by establishing and refning value-added registration processes, resources, and systems. The aims of [...]

2025-12-11T12:00:07+00:00December 12th, 2019|Tags: , , |

Kühler et al 2019 – To what degree are review outcomes aligned for new active substances between the EMA and the US FDA?

Objective To compare review outcome alignment between European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for medicines approved by both agencies in the time period 2014–2016. Design [...]

2026-02-05T16:37:13+00:00November 15th, 2019|Tags: , |

Keyter et al 2019 – South African Medicines Control Council: Comparison of Its Registration Process

Introduction: Comparisons between regulatory authorities of similar size and regulatory characteristics facilitate value-added benchmarking and provide insight into regulatory performance. Such comparisons highlight areas for improvement as authorities move [...]

2025-12-11T13:07:47+00:00March 14th, 2019|Tags: , , |

Bujar et al 2019 – Quality decision making in Health Technology Assessment

Background: To evaluate the quality of the decision-making processes of pharmaceutical companies during medicines development for evidence generation to support reimbursement of new medicines and the appraisal recommendation decision-making process [...]

2025-12-11T13:08:44+00:00March 4th, 2019|Tags: , |

Bujar et al 2019 – Reliability and relevance of a decision-making instrument

Introduction: The Quality of Decision-Making Orientation Scheme (QoDoS) was developed to provide organisations involved in submission, approval and reimbursement of new medicines with a tool to improve the quality [...]

2025-12-11T13:09:20+00:00January 31st, 2019|Tags: , , |

Wang et al 2018 – Building Synergy between Regulatory and HTA Agencies

Objectives: To evaluate the current practice of companies and agencies to assess the changes made in aligning regulatory and health technology assessment (HTA) stakeholders; to identify areas of commonality [...]

2025-12-11T13:11:35+00:00July 22nd, 2018|Tags: , , |

Haqaish et al 2017 – Jordan Food and Drug Administration: Comparison of its Registration Process with Australia, Canada, Saudi Arabia and Singapore

Objective: This study compares the current regulatory review process and good review practices at the Saudi Food and Drug Authority (SFDA) with those of regulatory agencies in Australia, Canada, [...]

2026-02-05T16:44:11+00:00January 1st, 2017|Tags: , |

Bujar et al 2016 – Quality of Regulatory Decision-Making Practices

Background The science of decision making is well established, although in reality it is a mixture of science and art. What is currently lacking is research into decision making [...]

2026-02-20T14:57:06+00:00December 30th, 2016|Tags: , |
Go to Top